Current Report Filing (8-k)
April 28 2014 - 8:41AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April
28, 2014
ANI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware |
001-31812 |
58-2301143 |
(State or other jurisdiction
of incorporation) |
(Commission File Number) |
(I.R.S. Employer
Identification Number) |
210 Main Street West
Baudette, Minnesota |
56623 |
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including
area code: (218) 634-3500
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item
2.02 | Results
of Operations and Financial Condition. |
On April 28, 2014, ANI Pharmaceuticals, Inc.
(“ANI”) issued a press release announcing that we will release our first quarter 2014 financial results on Monday,
May 5, 2014, before the opening of the U.S. financial markets. We will host a conference call with the investment community at
10:30am, Eastern Time on May 5, 2014. A copy of the press release is furnished as Exhibit 99.1 to this report.
In accordance
with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1,
shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference
into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such filing.
| Item
9.01 | Financial
Statements and Exhibits. |
(d) Exhibits
| 99.1 |
| Press
release, dated April 28, 2014, issued by ANI |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ANI PHARMACEUTICALS, INC. |
|
|
|
|
|
By: |
/s/ Charlotte C. Arnold |
|
|
|
Charlotte C. Arnold |
|
|
|
Vice President and Chief Financial Officer |
|
Dated: April 28, 2014 |
|
|
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Apr 2024 to May 2024
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From May 2023 to May 2024